Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September

REDWOOD CITY, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare conferences.

  • Management participation in a fireside chat is scheduled at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:30 a.m. ET taking place in Boston, MA.
  • Management participation in a fireside chat is scheduled at the Baird 2017 Global Healthcare Conference on Thursday, September 7th at 9:05 a.m. ET taking place in New York, NY.
  • A company presentation is scheduled at Cantor Fitzgerald’s 3rd Annual Healthcare Conference on Tuesday, September 26th at 8:35 a.m. ET taking place in New York, NY.

The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at

About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit

Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
+1 (650) 649-3527